Sulbactam/Durlobactam (Xacduro) for Acinetobacter Pneumonia

被引：0
作者：
不详
机构：
来源：
MEDICAL LETTER ON DRUGS AND THERAPEUTICS | 2023年 / 65卷 / 1690期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：189 / 190
页数：2
相关论文
共 6 条
[1]   Colistin and its role in the Era of antibiotic resistance: an extended review (2000-2019) [J].
Ahmed, Mohamed Abd El-Gawad El-Sayed ;
Zhong, Lan-Lan ;
Shen, Cong ;
Yang, Yongqiang ;
Doi, Yohei ;
Tian, Guo-Bao .
EMERGING MICROBES & INFECTIONS, 2020, 9 (01) :868-885
[2]  
[Anonymous], 2023, Approximate WAC. WAC = wholesaler acquisition cost or manufacturer's published price to wholesalers
[3]  
WAC represents a published catalogue or list price and may not represent an actual transactional price. Source: AnalySource<(R)> Monthly.
[4]   Sulbactam-durlobactam: A novel β-lactam-β-lactamase inhibitor combination targeting carbapenem-resistant Acinetobacter baumannii infections [J].
El-Ghali, Amer ;
Coyne, Ashlan Kunz J. ;
Caniff, Kaylee ;
Bleick, Callan ;
Rybak, Michael J. .
PHARMACOTHERAPY, 2023, 43 (06) :502-513
[5]  
Kaye KS, 2023, LANCET INFECT DIS, V23, P1072, DOI 10.1016/S1473-3099(23)00184-6
[6]   Durlobactam, a New Diazabicyclooctane β-Lactamase Inhibitor for the Treatment of Acinetobacter Infections in Combination With Sulbactam [J].
Shapiro, Adam B. ;
Moussa, Samir H. ;
McLeod, Sarah M. ;
Durand-Reville, Thomas ;
Miller, Alita A. .
FRONTIERS IN MICROBIOLOGY, 2021, 12
1